Evaxion reported a 75% objective response rate in a 16-patient Phase 2 study of EVX-01 plus pembrolizumab in first-line advanced melanoma, including four complete responses. Eleven of the twelve responders maintained responses at 24 months with no relapses among responders. Tumor reduction occurred in 15 of 16 patients, and 54% deepened their response category during treatment. Immune activation was detected in all patients, with 81% of vaccine-selected neoantigens eliciting specific T-cell responses. The regimen was well tolerated. Progression-free and overall survival data are not yet mature.
The company presented two-year data at ESMO and outlined an extension in which participants continue with EVX-01 monotherapy, with results expected in 2026. The trial’s primary endpoint—conversion to improved response category—was not formally analyzed due to reduced enrollment versus the original plan, although the observed 54% conversion rate would have supported it. This is a personalized peptide neoantigen vaccine designed by Evaxion’s AI-Immunology platform and manufactured per patient, administered alongside a PD-1 backbone.
Strategically, the readout positions Evaxion within the increasingly competitive space of individualized cancer vaccines combined with checkpoint inhibitors, where the bar is rising on the strength of randomized datasets and adjuvant studies. The durability signal at two years and high per-neoantigen immunogenicity are encouraging for a peptide-based approach, but the small, single-arm design and the absence of formal primary endpoint analysis limit interpretability. The company’s explicit need for a development partner underscores the capital and CMC intensity of personalized vaccines and suggests any registrational trajectory will be contingent on external funding and manufacturing alliances. Against the momentum of mRNA-based individualized vaccines paired with PD-1 therapy, Evaxion will need to articulate how a peptide construct can match or exceed efficacy while delivering reliable, scalable turnaround times and predictable quality.
For sites, this model demands tight orchestration of biopsy collection, rapid NGS, bioinformatics handoffs, and on-time dosing alongside standard pembrolizumab. Cold-chain handling, chain-of-identity/chain-of-custody, and scheduling discipline become core operational risks, especially across multi-center networks. CROs and vendors with integrated sequencing, data pipelines, and specialty logistics stand to benefit, while CDMOs with peptide capacity and validated release testing will be pivotal. Regulators will look for randomized evidence of additive benefit over PD-1 monotherapy, robust durability, and consistency across subgroups, along with a mature CMC package that demonstrates control over individualized manufacture and release. The observed immune correlates strengthen the biological rationale but will not substitute for survival endpoints or comparative data.
What to watch next is trial design and positioning. A randomized Phase 2/3 trial against pembrolizumab alone in first-line advanced melanoma would clarify the additive benefit, but sponsors are also pivoting earlier into adjuvant settings where event rates and regulatory paths differ. Time-to-vaccine from biopsy, manufacturing scalability, and site start-up velocity will be critical execution variables. Partner selection—whether big pharma for co-development on a PD-1 backbone or a CDMO alliance to lock in capacity—will signal how quickly Evaxion can move. The 2026 monotherapy extension readout may inform durability and maintenance strategies, but it will not replace the need for a controlled study. Key risks include competition for melanoma patients, operational complexity that can slow enrollment, and the comparative benchmark set by individualized mRNA vaccines already advancing with randomized data.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
